Docstoc

NCRI RADIOTHERAPY CLINICAL STUDIES GROUP

Document Sample
NCRI RADIOTHERAPY CLINICAL STUDIES GROUP Powered By Docstoc
					Annual report 2007-8



NCRI Radiotherapy Clinical Studies Group
Introduction
The Radiotherapy Clinical Studies Group continues to focus on quality assurance in
radiotherapy clinical trials, the evaluation of technical innovations in radiotherapy through the
Technology Subgroup, and translational research through the Translational Subgroup.

The Technology Subgroup chaired by Dr Philip Mayles has been interacting closely with
both ACORRN in developing a national strategy for the introduction and evaluation of image
guided radiotherapy (IGRT) and also through Dr Vincent Khoo interfacing with the ESTRO
Technology Development Group to ensure we are abreast of Pan European developments.

The Translational Subgroup, chaired jointly by Dr Catherine West and Professor John
Yarnold has continued to interface closely with the TRICC Committee enabling funding
applications for clinical trials programmes optimise their opportunities for good translational
work associated with the clinical dataset. The large genome studies RACE and RAPPER
are continuing successfully.

The past year has seen publications from two major multicentre NCRN radiotherapy trials
having significant impact on national and international practice. These are the START trial
of radiotherapy fractionation in breast radiotherapy and the RTO1 study in prostate cancer.

The Group underwent the second three yearly progress review in March 2008. The
international committee commended the Group on their work in radiotherapy quality
assurance and involvement in major trials affecting clinical practice (see Appendix 1).

The future work of the Group is currently under review in the light of the strategic review of
radiotherapy and radiobiology research by the NCRI. It is anticipated the Group will have a
wider remit including the development of phase I and phase II trials and closer interaction
with basic research. This will include incorporation of some roles previously undertaken by
ACORRN.

Membership and structure
We would like to extend a particular welcome to our two new consumer members, Ms Sue
Collins and Mrs Christine Young joining Mrs Joyce Pritchard who has been a founder
member of the group representing the Consumer Liaison Group. We are also grateful to
those members who have left and served the Group with considerable dedication and
enthusiasm over many years; Professor Sam Ahmedzai, Dr Jim Barber, Professor David
Dearnaley, Dr Anne Robinson and Professor Michele Saunders.

Portfolio and accrual
The clinical trials portfolio comprises 51 trials which have had input from the Radiotherapy
CSG either in their design, quality assurance or review processes.

605 patients were recruited to radiotherapy studies in 2007/08, representing 2.3% of total
incident cases. 120 were to RCTs and 485 were to non-RCTs. 403 patients were recruited in
2006/7.

A list of the studies in the portfolio can be found in Table 1 below:




                                                1
Annual report 2007-8




Table 1: Radiotherapy CSG Portfolio

  Acronym              Title                                          UK PI(s)         Status
ACT II                 A Second UK Phase III Anal Cancer Trial:      Professor Roger   Open
                       A Trial of Chemoradiation and                 James
                       Maintenance Therapy for Patients with
                       Anal Cancer
Adjuvant               Post operative chemo-radiotherapy after       Dr Mark           Closed
Stomach                surgical resection of gastric and             Saunders
Chemotherapy           oesophageal cancer. A multi-centre phase
                       I-II study of a fixed radiotherapy regimen
                       with concurrent chemotherapy with
                       escalating doses of capecitabine.
Anti-CD66              Targeted radiotherapy with conditioning       Dr Kim Orchard    Open
                       prior to haematopoletic stem cell
                       plantation- A randomised phase II clinical
                       trial using targeted radiotherapy delivered
                       by an Yttrium 90 radiolabelled anti-CD66
                       monclonal antibody with high dose
                       melphalan compared to melphalan alone,
                       prior to autologous stem cell
                       transplantation for multiple myeloma
ASTEC                  A Randomised Trial of Lymphadenectomy         Dr Peter Blake    Closed
                       and of adjuvant External beam
                       Radiotherapy in the Treatment of
                       Endometrial Cancer
BASO DCIS II           Randomised trial testing observation (no      Professor Nigel   Closed
Trial                  radiotherapy) against radiotherapy in         Bundred
                       women with low-risk completely excised
                       ER positive ductal carcinoma in situ
                       (DCIS) of the breast on adjuvant
                       endocrine therapy.
BC2001                 A randomised phase II study of                Dr Robert         Open
                       synchronous radiotherapy in muscle            Huddart
                       invasive bladder cancer.
ON                     A Multicentre Randomised Trial of Radical     Dr Robert         Closed
                       Radiotherapy with Carbogen in the             Huddart
                       Radical Radiotherapy of Locally Advanced
                       Bladder Cancer
BNLI Radiation         BNLI Randomised trial of radiation dose in                      Closed
Dose                   non-Hodgkin's lymphoma
I Snford V             Protocol for a randomised phase III study     Professor Peter   Closed
                       of the Stanford V regimen, compared with      Hskin
                       ABVD for the treatment of advanced
                       Hodgkin's disease
BS06                   A Randomised Study of Radical                 Dr Stephen        Closed
                       Radiotherapy in the Management of             Harland
                       pT1G3 NxM0 Transitional Cell Carcinoma
                       of the Bladder
CHARTWEL               A Randomised Controlled Trial of              Professor S       Closed
                       CHARTWEL (a continuous                        Dische
                       hyperfractionated accelerated



                                                  2
Annual report 2007-8

                       radiotherapy schedule) versus
                       conventional radiotherapy in post-
                       operative head and neck cancer patients.
CHHIP                  Conventional or Hypofractionated High          Professor David    Open
                       Dose Intensity Modulated Radiotherapy          Dearnaley
                       for Prostate Cancer
CR07                   A Randomised Trial Comparing Pre-              Professor Martin   Closed
                       Operative Radiotherapy and Selective           Birchall
                       Post-Operative Chemoradiotherapy in
                       Rectal Cancer
EaStER                 Early Stage glottic cancer: Endoscopic         Professor Martin   Open
Feasibility            excision or Radiotherapy - Feasibility         Birchall
Study                  study
EORTC 10981            After mapping of the axilla: Radiotherapy      Professor Robert   Open
                       or Surgery: EORTC 10981-22023                  Mansel
EORTC 22922            Phase III randomized trial investigating the   Walter Van Den     Closed
                       role of internal mammary and medial            Bogaert
                       supraclavicular (IM-MS) lymph node chain
                       irradiation in stage I-III breast cancer
                       (Joint study of the EORTC Radiotherapy
                       Cooperative Group and the EORTC
                       Breast Cancer Coopera
EORTC 22952            No Radiotherapy versus Whole Brain             Dr R Soffietti     Closed
                       Radiotherapy for 1 to 3 Brain Metastases
                       from Solid Tumor after Surgical Resection
                       or Radiosurgery. A Randomized Phase III
                       Trial.
EORTC 22991            Three Dimensional Conformal                    Professor          Closed
                       Radiotherapy / Intensity Modulated             Malcolm Mason
                       Radiotherapy alone vs Three Dimensional
                       Conformal Radiotherapy / Intensity
                       Modulated Radiotherapy plus adjuvant
                       hormonal therapy in localised T1b-c, T2a,
                       N0, M0 prostatic carcinoma.
EORTC 55985            Phase II clinical trial on Taxol as single     Professor John A   Closed
                       agent in locally advanced and/or               Green
                       metastatic or recurrent vulva cancer not
                       amenable for surgery and/or radiotherapy-
                       EORTC trial 55985
EORTC 62991            Phase II pilot of moderate radiotherapy for    Dr Martin          Open
                       inoperable aggressive fibromatosis             Robinson
EXTRA                  Evaluation of Xeloda Treatment with            Dr Rob Glynne-     Closed
                       radiotherapy in Anal Cancer                    Jones
FAST                   Prospective randomised clinical trial          Professor John     Closed
                       testing 5.7Gy and 6.0Gy fractions of whole     Yarnold
                       breast radiotherapy in terms of late normal
                       tissue responses and tumour control
FORT                   FORT                                           Professor Peter    Open
                                                                      Hoskin
GOLDSEED               Evaluation of tumour bed localisation and      Dr Charlotte       Closed
                       image-guided radiotherapy techniques for       Coles
                       breast radiotherapy
HER-PCI                Prospective randomised clinical trial          Dr Peter Canney    Open
                       testing the role of prophylactic cranial


                                                   3
Annual report 2007-8

                       radiotherapy in patients treated with
                       Trastuzumab (Herceptin) for metastatic
                       breast cancer
High Dose              High Activity Rhenium-186 HEDP with             Professor David    Closed
Rhenium                peripheral blood stem cell support in           Dearnaley
                       patients with bony metastases in prostate
                       cancer.
IMPORT HIGH            Randomised trial testing dose escalated         Professor John     in Set-
                       intensity modulated radiotherapy in             Yarnold            up
                       women with higher than average local
                       tumour recurrence risk after breast
                       conservation surgery and appropriate
                       systemic therapy for early breast cancer
IMPORT LOW             Randomised trial testing intensity              Professor John     Open
                       modulated and partial organ radiotherapy        Yarnold
                       following breast conservation surgery for
                       early breast cancer
IMRT trial             Radiotherapy in early breast cancer:            Dr Margaret        Closed
                       cosmetic outcome                                Moody
MARS                   Mesothelioma and Radical Surgery trial.         Professor Julian   Open
                       MARS pilot study - to determine the             Peto
                       feasibility and acceptability of performing a
                       randomised trial comparing extra-pleural
                       pneumonectomy (EPP) against no EPP
                       surgery within the context of trimodality
                       therapy (chemot
ORBIT                  Effective management of radiation-              Dr Jervoise        Open
                       induced bowel injury: A randomised              Andreyev
                       controlled trial
PARSPORT               A multicentre randomised study of parotid       Dr Christopher     Open
                       sparing intensity-modulated radiotherapy        Nutting
                       in patients with head and neck cancer
PR07                   A Randomised trial of Hormone Therapy           Professor          Closed
                       plus Radical radiotherapy versus                Malcolm Mason
                       Hormone Therapy alone in Non-Metastatic
                       Prostate Cancer
PRIME                  The PRIME breast cancer trial                   Professor Robin    Closed
                       (postoperative radiotherapy in minimum-         Prescott
                       risk elderly)
PRIME II               Post-operative Radiotherapy In Minimum-         Dr Ian Kunkler     Open
                       risk Elderly Phase II
Prostate HDR           Randomised trial of interstitial                                   Closed
brachytherapy          brachythearpy as a component of radical
boost trial            radiotherapy for localised prostatic cancer
ProtecT                The ProtecT Trial - Evaluating the              Professor Jenny    Open
                       effectiveness of treatment for clinically       Donovan
                       localised prostate cancer
QUARTZ                 A phase III multicentre randomised              Dr Paula           Open
                       controlled trial to assess whether optimal      Mulvenna
                       supportive care (including
                       dexamethasone) alone is as effective as
                       optimal supportive care (including
                       dexamethasone) and whole brain
                       radiotherapy (WBRT) in the treatment of


                                                   4
Annual report 2007-8

                       patients with inoperable brain metastases
                       from non-small cell lung cancer (NSCLC).
RACE                   Radiation Complications and                    Professor John     Closed
                       Epidemiology – Inherited factors               Yarnold
                       contributing to radiotherapy side effects
RAPPER                 Radiogenomics: assessment of                   Dr Catharine       Open
                       polymorphisms for predicting the effects of    West
                       radiotherapy
RIB                    A multicentre randomised trial of single       Professor Peter    Open
                       dose Radiotherapy compared to                  Hoskin
                       Ibandronate for localised metastatic bone
                       pain
RT with Weekly         Phase II study of radiotherapy with            Dr Richard         Closed
GEM                    concurrent weekly gemcitabine in muscle-       Cowan
                       invasive bladder cancer.
SC20                   A phase III international randomised trial     Professor Peter    Open
                       of single vs multiple fractions of re-         Hoskin
                       irradiation of painful bone metastases.
SCORAD                 A randomised feasibility study of single       Professor Peter    Open
                       fraction radiotherapy compared to multi-       Hoskin
                       fraction radiotherapy in patients with
                       metastatic spinal cord compression
SECRAB                 Sequencing of Chemotherapy and                 Dr Indy Fernando   Closed
                       Radiotherapy in Adjuvant Breast Cancer
Skin Study             A Randomised, Double-Blind Controlled          Dr Andrew          in Set-
                       Trial of Mometosone Furoate Cream              Hindley            up
                       Versus Placebo to Prevent Radiation
                       Dermatitis of the Breast and Chest Wall
SOCCAR                 Sequential or Concurrent Chemotherapy          Dr Joe Maguire     Open
                       and radiotherapy in NSCLC
START                  Standardisation of Breast Radiotherapy         Professor John     Closed
                       (START) Trial                                  Yarnold
SUPREMO                Selective use of postmastectomy                Dr Peter Canney    Open
                       radiotherapy after mastectomy
TRAPEZE (PIII)         A randomised phase II/III trial of docetaxel   Professor          Open
                       plus prednisolone vs. docetaxel plus           Nicholas James
                       prednisolone plus zoledronic acid vs.
                       docetaxel plus prednisolone plus
                       strontium-89 vs. docetaxel plus
                       prednisolone plus zoledronic acid plus
                       strontium-89 in hormone refractory
                       prostate cancer metastatic to bone
VORTEX                 - Randomised trial evaluating impact of        Dr Martin          Open
                       changes in volume of post-operative            Robinson
                       radiotherapy on morbidity and limb
                       function in adult patients with extremity
                       soft tissue sarcoma

The Radiotherapy Quality Assurance Group has a portfolio of 12 trials for which they are
providing active QA programmes and a further 7 trials currently in set-up which will require
their support and input.




                                                   5
Annual report 2007-8



Trials in development
Currently the Radiotherapy CSG has no trials specific to the Group alone in development. A
number of initiatives in collaboration with other clinical study groups however are in progress
including evaluation of dose escalation in non-small cell lung cancer, further evaluation of
intensity modulated radiotherapy in head and neck cancer, evaluation of PET in radiotherapy
planning in head and neck cancer, involved node radiotherapy in Hodgkins lymphoma,
further assessment of hypofractionation and treatment time in breast cancer, chemoradiation
in bladder and oesophageal cancer and involved node radiotherapy in young adults
Hodgkins lymphoma.

In addition translational projects related to completed trials are in development, translational
studies linked to the START trial are under development. The BCON trial of radiotherapy
with carbogen and nicotinomide will be used to explore the ability of a hypoxi a-associated
gene signature to predict benefit from hypoxia-modifying therapy (planned outline proposal
to be submitted to TRICC March 2008). Outline proposals have been developed for
translational studies linked to the CHARTWELL and EASTER trials and are awaiting
analysis of trial data and evidence of satisfactory patient recruitment, respectively.

Meetings
The Group did not hold an annual meeting in 2007/8 but are discussing proposals to hold
one based around chemoradiation in the coming reporting year.

Collaborations
The activities of the Radiotherapy CSG are closely integrated with the relevant professional
bodies to those disciplines involved in radiotherapy, in particular The Royal College of
Radiologists, College of radiographers, the Institute of Physics and Engineering in Medicine
(IPEM) and the British Institute of Radiology (BIR). We have links with the EORTC
Radiotherapy Group through Mrs Mary Coffey who is a member of both groups providing
cross-representation and feedback from the EORTC meetings and with the Chairman of the
EORTC group, Dr Karen Haustermanns. We have interaction with ESTRO through the
cross-representation by Dr Vincent Khoo who chairs ESTRO Technologies Group. We have
been closely associated with ACORRN having established a formal ACORRN representative
sitting on the RT CSG.




                                               6
Annual report 2007-8

Appendix 1

Key strengths and issues from the Progress Review, March 2008

The key strengths of the Group identified at the review are:

   Their role in quality assurance and the positive effect this has had in improving
    radiotherapy within trials
   Accrual to some studies which have changed practice
   Recruiting a range of specialisms and younger researchers onto the Group and its
    subgroups

The Panel considered Radiotherapy to be an important area of research and one which the
funders wished to continue to support and see expanded. The Panel recommended that the
RTCSG, its role and therefore composition, should be further considered once the NCRI
review of radiotherapy and radiobiology had taken place and had identified the priorities and
objectives for research over the next few years.




                                              7
Annual report 2007-8

Appendix 2

2006/07 Publications and abstracts


Ng Q-S, Goh V, Milner J Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ.
Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I
study. . Lancet Oncology 2007,8 (2) 111-118.

Dewar JA, Haviland JS, Agrawal RK, Bliss JM, Hopwood P, Magee B, Owen JR,
Sydenham MA, Venables K, Yarnold JR, and on behalf of the START Trialists.
Hypofractionation for early breast cancer: First results of the UK standardization of breast
radiotherapy (START) Trials. JCO 25(18S (June 20 Supplement): LBA518). 2007. Ref Type:
Abstract

Hopwood P, Mills J, Sumo G, Haviland J, Bliss JM, and on behalf of the START Trial
Management Group. Prevalence patterns and predictors of mood disorders in early breast
cancer: Results from 2208 women in the START (Standardisation of Breast Radiotherapy)
Trial. Psychiatry Meeting, Amsterdam . 2007. Ref Type: Abstract

Hopwood P on behalf of the START & TACT Trial Management Group. QOL data from 2
large breast cancer clinical trials. NCRI Conference 2006. Ref Type: Abstract

Hopwood P, Haviland J, Mills J, Sumo G, Bliss M. The impact of age and clinical factors
on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK
START Trial (Standardisation of Breast Radiotherapy Trial). Breast 2007 Jun;16(3):241-51.

West CM, Elliott RM, Burnet NG: The genomics revolution and radiotherapy. Clin Oncol (R
Coll Radiol) 19:470-80, 2007

McCarthy HO*, Worthington J*, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C,
McKeown SR, Hirst DG, Robson T. p21(WAF-1)-mediated transcriptional targeting of iNOS
gene therapy sensitizes tumours to fractionated radiotherapy. (*Both authors contributed
equally to this paper). Gene Ther. 14(3):246-55.

Robinson A. Oral Sodium Clodronate for Non metastatic Prostate Cancer -- Results of a
randomidsed Double-Blind Placebo Contolled Trial: The Medical Research Council J Natl
Cancer Inst 2007 ;99: 1-13

Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, PeckittT C, Reise
S, Ross G, Sharp G, Symonds-Tayler R, Tait D, Yarnold J. Randomised trial of standard
2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed
breast radiotherapy. Radiother Oncol 2007; 82: 254-264

Hopwood P, Sumo G, Mills J, Haviland J, Bliss JM, Yarnold J, on behalf of the START
Trial Management Group. Patient rated breast symptoms and body image in early breast
cancer: first results of the UK standardistaion of breast radiotherapy (START) trials. San
Antonio Breast Cancer Symposium December 2007. Ref Type: Abstract

Yarnold JR, Owen JR, Dewar JA, Haviland JS, Agrawal RK, Bliss JM, Hopwood P,
Magee B, Sydenham MA, Venables K on behalf of the START Trialists. Results of the
UK standardisation of breast radiotherapy (START) trials testing hypofractionation for early
breast cancer. NCRI Cancer Conference October 2007. Ref Type: Abstract




                                              8
Annual report 2007-8

Mills J, Haviland J, Brown J, Hopwood P, Bliss JM, on behalf of the START Trial
Management Group. How soon do patients return to paid and unpaid activities after
radiotherapy treatment for early stage breast cancer? NCRI Cancer Conference October
2007. Ref Type: Abstract

Hopwood P, Mills J, Sumo G, Haviland J, Bliss JM, on behalf of the START Trial
Management Group. Prevalence, patterns and predictors of mood disorders in early breast
cancer: results from 2208 women in the UK Standardisation of Breast Radiotherapy Trial
(START). NCRI Cancer Conference October 2007. Ref Type: Abstract

Mills J, Bliss JM, Hopwood P, on behalf of the START Trial Management Group. How
to generate quality in ‘Quality of Life’ studies: experiences from a radiotherapy trial for early
stage breast cancer (START Trial). NCRI Cancer Conference October 2007. Ref Type:
Abstract

Hopwood P, Sumo G, Mills J, Haviland J, Bliss J, Yarnold J, on behalf of the START
Trial Management Group. Body image and breast symptoms in early breast cancer: first
results of the UK standardisation of breast radiotherapy (START) trials. NCRI Cancer
Conference October 2007. Ref Type: Abstract

Elliott RM, Burnet NG, Dunning AM, Dearnaley DP, Coles CE, West CML on behalf of
RAPPER collaborators. Radiogenomics: Assessment of Polymorphisms for Predicting the
Effects of Radiotherapy NCRI Cancer Conference 2007

Owen JR, Dewar JA, Haviland JS, Agrawal RK, Bliss JM, Hopwood P, Magee B,
Sydenham MA, Venables K, Yarnold JR on behalf of the START Trialists. Results of the
UK standardisation of breast radiotherapy (START) trials testing hypofractionation for early
breast cancer. ECCO 14, September 2007. Ref Type: Abstract

Sydenham M, Haviland J, Gothard L, Tait D, Yarnold J on behalf of START Trial
Management Group. Scoring photographic assessment of normal tissue effects after
radiotherapy for early breast cancer. ECCO 14, September 2007. Ref Type: Abstract

Lawton PA, Aird E, Bliss JM, Haviland J, Magee B, Sydenham M, Venables K, Yarnold
J on behalf of the START Trial Management Group. The effect of hypofractionation and
radiation dosimetry on the incidence of symptomatic rib fractures in women treated with
radiotherapy for early breast cancer in the UK standardisation of breast radiotherapy
(START) Trials. ECCO 14, September 2007. Ref Type: Abstract

Hopwood P, Sumo G, Mills J, Haviland J, Bliss J, Yarnold J, on behalf of the START
Trial Management Group. Body image and breast symptoms in early breast cancer: first
results of the UK standardisation of breast radiotherapy (START) trials. ECCO 14,
September 2007 . Ref Type: Abstract

Hopwood P, Mills J, Sumo G, Haviland J, Bliss JM, on behalf of the START Trial
Management Group. Prevalence, patterns and predictors of mood disorders in early breast
cancer: results from 2208 women in the UK Standardisation of Breast Radiotherapy Trial
(START). ECCO 14, September 2007 . Ref Type: Abstract

Hoskin PJ, Dearnaley DP. Hypofractionation in clinical trials for prostate cancer. Clin Oncol
(R Coll Radiol). 2007 Jun;19(5):287-8

Elliott RM, Hughes A, Irlam-Jones J, Grimer R, Hughes DE, Billingham LJ, Robinson
MH, West CML: VORTEX-BIOBANK: Translational Tissue Banking Study. NCRI Cancer
Conference October 2007. Ref Type: Abstract


                                                9
Annual report 2007-8



Elliott RM, Burnet NG, Dunning A, Dearnaley DP, Coles CE, West CM: Radiosensitivity,
radiogenomics and RAPPER. NCRI Cancer Conference October 2007. Ref Type: Abstract

Elliott RM, Hughes A, Irlam-Jones J, Grimer R, Hughes DE, Billingham LJ, Robinson
MH, West CML: VORTEX-BIOBANK: Prospective sample collection for the VORTEX
randomised radiotherapy trial in patients with extremity soft tissue sarcoma. British Sarcoma
Group Meeting, Sheffield, January 2008 Ref Type: Abstract

South C P, Khoo V S, Naismith O, Norman A, Dearnaley DP, A Comparison of Treatment
Planning Techniques Used in Two Randomised UK External Beam Radiotherapy Trials for
Localised Prostate Cancer. Clin Oncol (R Coll Radiol). 2007 Dec 1

Dearnaley DP. Additional treatment for pT3 prostate cancer: now, later or never. BJU Int.
2007 Nov;100(5):977-9. Epub 2007 Sep 10.

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA,
Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC, Russell JM, Scrase CD,
Stephens RJ, Syndikus I, Parmar MK; RT01 collaborators. Escalated-dose versus
standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01
randomised controlled trial. Lancet Oncol. 2007 Jun;8(6):475-87.

Urbano TG, Clark CH, Hansen VN, Adams EJ, Miles EA, Mc Nair H, Bidmead AM,
Warrington J, Dearnaley DP, Harmer C, Harrington KJ, Nutting CM. Intensity Modulated
Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I
study. Radiother Oncol. 2007 Oct;85(1):58-63. Epub 2007 Sep 27.

Khoo VS, Dearnaley DP. Question of Dose, Fractionation and Technique: Ingredients for
Testing Hypofractionation in Prostate Cancer - the CHHiP Trial. Clin Oncol (R Coll Radiol).
2007 Nov 22 [Epub ahead of print]

Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, Nutting
CM, PARSPORT Trial Management Group Target volume definition for head and neck
intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin
Oncol (R Coll Radiol). 2007 Oct;19(8):604-13. Epub 2007 Aug 13.

Naismith OF, Dearnaley DP, Bidmead AM. Use of Rectal DSHs to Compare Forward and
Inverse IMRT Treatment Planning for Prostate Cancer. Clin Oncol (R Coll Radiol). 2007
Apr;19(3 Suppl):S41

McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C,
McKeown SR, Hirst DG, Robson T. (2007) p21(WAF-1)-mediated transcriptional targeting
of iNOS gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther.
14(3):246-55

McKeown SR, Cowen RL, Williams KJ. Bioreductive Drugs: from Concept to Clinic. Clin
Oncol. (Royal Coll Radiol) 2007; 19(6):427-42

McKenna DJ, McKeown SR, McKelvey-Martin VJ. Potential use of the comet assay in the
clinical management of cancer. Mutagenesis. 2008 May;23 (3):183-90.

O’Rourke M, Ward C, McKenna J, Worthington J, Valentine A, Hirst DG, McKeown SR.
Evaluation of the anti-angiogenic potential of AQ4N. Clin Cancer Res. 2008 Mar
1;14(5):1502-9.



                                             10
Annual report 2007-8

Butterworth KT, McCarthy HO, Devlin AH, Ming L, Robson T, McKeown SR,
Worthington J. Hypoxia selects for invasive, androgen independent and apoptosis resistant
LNCaP cells. Int. J Cancer. 2008, 29 May [Epub ahead of print].

O’Keeffe MB, Devlin AH, Burns AJ, Gardiner TA, Logan ID, Hirst DG, McKeown SR .
Investigation of pericytes, hypoxia and vascularity in bladder tumours: association with
clinical outcomes. Oncology Res. In press

Devlin AH, McIlroy M, McKeen HD, Bonde P, Menezes AAC, Bell Z, Swarbrick CJ,
Robson T, DG Hirst, Campbell FC, McGuigan JA, McKeown SR. Cytochrome P450 1B1
expression in rat oesophageal tumorigenesis promoted by gastric and duodenal reflux.
Molecular Carcinogenesis. In press

Berridge J., Coffey M. Workload Measurement.
Applied Clinical Trials Volume 17, Number 6 June 2008




                                           11

				
DOCUMENT INFO